Cargando…

Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients

BACKGROUND: Antibody levels against SARS-CoV-2 can be used as an indicator of recent or past vaccination or infection. However, the prognostic value of antibodies targeting the receptor binding protein (anti-RBD) in hospitalized patients is not widely reported. PURPOSE: Determine prognostic impact o...

Descripción completa

Detalles Bibliográficos
Autores principales: Madanat, Luai, Sager, Melinda, O’Connor, Daniel, Thapa, Bijaya, Aggarwal, Nishant, Ghimire, Bipin, Lauter, Carl, Maine, Gabriel N, Sims, Matthew, Halalau, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215841/
https://www.ncbi.nlm.nih.gov/pubmed/35755860
http://dx.doi.org/10.2147/IJGM.S370080
_version_ 1784731297502986240
author Madanat, Luai
Sager, Melinda
O’Connor, Daniel
Thapa, Bijaya
Aggarwal, Nishant
Ghimire, Bipin
Lauter, Carl
Maine, Gabriel N
Sims, Matthew
Halalau, Alexandra
author_facet Madanat, Luai
Sager, Melinda
O’Connor, Daniel
Thapa, Bijaya
Aggarwal, Nishant
Ghimire, Bipin
Lauter, Carl
Maine, Gabriel N
Sims, Matthew
Halalau, Alexandra
author_sort Madanat, Luai
collection PubMed
description BACKGROUND: Antibody levels against SARS-CoV-2 can be used as an indicator of recent or past vaccination or infection. However, the prognostic value of antibodies targeting the receptor binding protein (anti-RBD) in hospitalized patients is not widely reported. PURPOSE: Determine prognostic impact of SARS-CoV-2 antibody quantification at the time of admission on clinical outcomes in hospitalized COVID-19 patients. METHODS: We conducted a pilot observational study on patients hospitalized with SARS-CoV-2 infection to determine the prognostic impact of antibody quantitation within the first two days of admission. Anti-nucleocapsid IgG (anti-N) and Anti-RBD levels were measured. Anti-RBD level of 500 AU/mL was used as a cutoff to stratify patients. Spearman’s rank Coefficient (r(s)) was used to demonstrate association. RESULTS: Of the 26 patients included, those who were vaccinated more frequently tested positive for Anti-RBD (100% vs 46.2%, P = 0.005) with higher median titer level (623 vs 0, P = 0.011) compared to unvaccinated patients. Anti-N positivity was more frequently seen in unvaccinated patients (53.9% vs 7.7%, P = 0.03). Anti-RBD levels >500 were associated with lower overall hospital length of stay (LOS)(5 vs 10 days, P = 0.046). The analysis employing a Spearman Rank coefficient demonstrated a strong negative correlation between anti-S titer and LOS (r(s)=−.515, p = 0.007) and a moderate negative correlation with oxygen needs (r(s) =−.401, p = 0.042). CONCLUSION: Anti-RBD IgG levels were associated with lower LOS and oxygen needs during hospitalization. Further studies are needed to determine if levels on admission can be used as a prognostic indicator.
format Online
Article
Text
id pubmed-9215841
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92158412022-06-23 Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients Madanat, Luai Sager, Melinda O’Connor, Daniel Thapa, Bijaya Aggarwal, Nishant Ghimire, Bipin Lauter, Carl Maine, Gabriel N Sims, Matthew Halalau, Alexandra Int J Gen Med Short Report BACKGROUND: Antibody levels against SARS-CoV-2 can be used as an indicator of recent or past vaccination or infection. However, the prognostic value of antibodies targeting the receptor binding protein (anti-RBD) in hospitalized patients is not widely reported. PURPOSE: Determine prognostic impact of SARS-CoV-2 antibody quantification at the time of admission on clinical outcomes in hospitalized COVID-19 patients. METHODS: We conducted a pilot observational study on patients hospitalized with SARS-CoV-2 infection to determine the prognostic impact of antibody quantitation within the first two days of admission. Anti-nucleocapsid IgG (anti-N) and Anti-RBD levels were measured. Anti-RBD level of 500 AU/mL was used as a cutoff to stratify patients. Spearman’s rank Coefficient (r(s)) was used to demonstrate association. RESULTS: Of the 26 patients included, those who were vaccinated more frequently tested positive for Anti-RBD (100% vs 46.2%, P = 0.005) with higher median titer level (623 vs 0, P = 0.011) compared to unvaccinated patients. Anti-N positivity was more frequently seen in unvaccinated patients (53.9% vs 7.7%, P = 0.03). Anti-RBD levels >500 were associated with lower overall hospital length of stay (LOS)(5 vs 10 days, P = 0.046). The analysis employing a Spearman Rank coefficient demonstrated a strong negative correlation between anti-S titer and LOS (r(s)=−.515, p = 0.007) and a moderate negative correlation with oxygen needs (r(s) =−.401, p = 0.042). CONCLUSION: Anti-RBD IgG levels were associated with lower LOS and oxygen needs during hospitalization. Further studies are needed to determine if levels on admission can be used as a prognostic indicator. Dove 2022-06-18 /pmc/articles/PMC9215841/ /pubmed/35755860 http://dx.doi.org/10.2147/IJGM.S370080 Text en © 2022 Madanat et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Madanat, Luai
Sager, Melinda
O’Connor, Daniel
Thapa, Bijaya
Aggarwal, Nishant
Ghimire, Bipin
Lauter, Carl
Maine, Gabriel N
Sims, Matthew
Halalau, Alexandra
Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
title Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
title_full Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
title_fullStr Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
title_full_unstemmed Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
title_short Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients
title_sort prognostic value of sars-cov-2 anti-rbd igg antibody quantitation on clinical outcomes in hospitalized covid-19 patients
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215841/
https://www.ncbi.nlm.nih.gov/pubmed/35755860
http://dx.doi.org/10.2147/IJGM.S370080
work_keys_str_mv AT madanatluai prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT sagermelinda prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT oconnordaniel prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT thapabijaya prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT aggarwalnishant prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT ghimirebipin prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT lautercarl prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT mainegabrieln prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT simsmatthew prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients
AT halalaualexandra prognosticvalueofsarscov2antirbdiggantibodyquantitationonclinicaloutcomesinhospitalizedcovid19patients